Premium
Lessons Learned: Transfer of the High‐Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform
Author(s) -
Kuhn P,
Keating SM,
Baxter GT,
Thomas K,
Kolatkar A,
Sigman CC
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.645
Subject(s) - commercialization , new product development , technology transfer , product (mathematics) , technology development , key (lock) , computer science , engineering management , process management , knowledge management , business , engineering , manufacturing engineering , marketing , geometry , mathematics , computer security
Planning and transfer of a new technology platform developed in an academic setting to a start‐up company for medical diagnostic product development may appear daunting and costly in terms of complexity, time, and resources. In this review we outline the key steps taken and lessons learned when a technology platform developed in an academic setting was transferred to a start‐up company for medical diagnostic product development in the interest of elucidating development toolkits for academic groups and small start‐up companies starting on the path to commercialization and regulatory approval.